Partnership set to advance translational research in human rejuvenation – Michael Greve’s Forever Healthy Foundation commits $5 million to fund breakthrough science with strong potential for start up creation at the Buck Institute.
The Forever Healthy Foundation and the Buck Institute for Research on Aging today announced a new partnership to advance early-stage discoveries at the Institute that show promise to reverse physiologic aging in humans. The focus will be on cutting-edge research aimed at the repair of age-related damage at the cellular and molecular level, a hallmark of the aging process. Forever Healthy will commit up to $1 million per year for five years to drive this innovation, with the funding aiming to advance early-stage research with high translational potential in order to speed up the transition from lab to product.
Longevity.Technology: German entrepreneur and longevity pioneer Michael Greve founded his humanitarian Forever Healthy initiative with the mission of accelerating the development of therapies to impede the aging process and the diseases that accompany it. This mission is in perfect alignment with the Buck Institute, the first independent biomedical facility in the world focused solely on the biology of aging.
Greve first established a relationship with Buck science in 2016 when he supported research in the labs of Judith Campisi, PhD, one of the leading global figures in the study of cellular senescence, and Julie Andersen, PhD, a prominent researcher working to find new therapeutic interventions for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. “I am really impressed with Buck science,” said Greve, “and view this enhanced partnership as the next step in translating research on aging into preventative therapies for people everywhere.”
“We are most appreciative of Michael’s generosity and vision,” said Eric Verdin, MD, President, and CEO of the Buck Institute. “It is an incredible and exciting time for our field, and we are delighted to be working with Forever Healthy as we move toward translational research.”
